• Products
    • Pritumumab
    • CLNH5
    • MultiPharm
  • Investors
    • Corporate Governance
    • Contact Investor Relations
  • News
  • About
    • Corporate Management
    • Board of Directors
    • Science Advisory Board
  • Contact
Development and delivery of human antibodies for the treatment of cancer Development and delivery of human antibodies for the treatment of cancer Development and delivery of human antibodies for the treatment of cancer
  • Products
    • Pritumumab
    • CLNH5
    • MultiPharm
  • Investors
    • Corporate Governance
    • Contact Investor Relations
  • News
  • About
    • Corporate Management
    • Board of Directors
    • Science Advisory Board
  • Contact

Corporate News

 Nascent Biotech Regains Worldwide Rights for Pritumumab
0
By Nascent Biotech
In Corporate News
Posted May 27, 2023

Nascent Biotech Regains Worldwide Rights for Pritumumab

NORTH PALM BEACH, FL / ACCESSWIRE / May 26, 2023 / Nascent Biotech, Inc. (OTCQB:NBIO) (“Nascent Biotech”, “Nascent”, or the “Company”), a clinical-stage [...]

READ MORE
 NBIO Link Report for May 10, 2023
0
By Nascent Biotech
In Corporate News
Posted May 10, 2023

NBIO Link Report for May 10, 2023

Wall Street PR Apple News StreetInsider.com QuoteMedia WallStreetPR Facebook LinkedIn

READ MORE
 Nascent Biotech to Present Phase I Clinical Data at American Society of Clinical Oncology Annual Meeting
0
By Nascent Biotech
In Corporate News, Press Releases, Science News
Posted May 9, 2023

Nascent Biotech to Present Phase I Clinical Data at American Society of Clinical Oncology Annual Meeting

NORTH PALM BEACH, FL / ACCESSWIRE / May 9, 2023 / Nascent Biotech, Inc. (OTCQB:NBIO) (“Nascent Biotech”, “Nascent”, or the “Company”), a clinical-stage [...]

READ MORE
 A Letter to Nascent Biotech Shareholders, May 1, 2023
0
By Nascent Biotech
In Corporate News, News
Posted May 1, 2023

A Letter to Nascent Biotech Shareholders, May 1, 2023

Dear Shareholder, Your continued support of Nascent Biotech is very much appreciated by the Company’s management.  Without it, we could not have achieved the completion of our Phase I Clinical [...]

READ MORE
 Nascent Submits Phase 2 Clinical Research Protocol to FDA for Review and Approval
0
By Nascent Biotech
In Corporate News, News, Press Releases, Science News
Posted April 18, 2023

Nascent Submits Phase 2 Clinical Research Protocol to FDA for Review and Approval

NORTH PALM BEACH, FL / ACCESSWIRE / April 18, 2023 / Nascent Biotech, Inc. (OTCQB:NBIO) (“Nascent Biotech”, “Nascent”, or the “Company”), a clinical-stage [...]

READ MORE
 Nascent Announces the Completion of Its Phase 1 Clinical Trials
0
By Nascent Biotech
In Corporate News, Press Releases, Science News
Posted February 28, 2023

Nascent Announces the Completion of Its Phase 1 Clinical Trials

NORTH PALM BEACH, FL / ACCESSWIRE / February 28, 2023 / Nascent Biotech, Inc. (OTCQB:NBIO) (“Nascent Biotech”, “Nascent”, or the “Company”), a clinical-stage [...]

READ MORE
 NBIO Fits Profile for Strategy Targeting Early Stage Biotech
0
By Nascent Biotech
In Corporate News
Posted January 18, 2023

NBIO Fits Profile for Strategy Targeting Early Stage Biotech

One candidate that checks all of these boxes is Nascent Biotech Inc. (OTCMKTS:NBIO). NBIO checks all the boxes discussed above. It’s a dirt-cheap stock, trading on a market cap of just $16 [...]

READ MORE
 Nascent Biotech Announces Appointment of Dr. Ivan Babic to Scientific Advisory Board
0
By Nascent Biotech
In Corporate News, Press Releases, Science News
Posted December 20, 2022

Nascent Biotech Announces Appointment of Dr. Ivan Babic to Scientific Advisory Board

VERO BEACH, FL / ACCESSWIRE / December 20, 2022 / Nascent Biotech, Inc. (OTCQB:NBIO) (“Nascent Biotech”, “Nascent”, or the “Company”), a clinical-stage [...]

READ MORE
 Nascent Biotech Receives Notice of the Issuance of US Patent No.11,494,394
0
By Nascent Biotech
In Corporate News, News, Press Releases, Science News
Posted November 1, 2022

Nascent Biotech Receives Notice of the Issuance of US Patent No.11,494,394

VERO BEACH, FL / ACCESSWIRE / November 1, 2022 / Nascent Biotech, Inc. (OTCQB:NBIO) (“Nascent Biotech”, “Nascent”, or the “Company”), a clinical-stage [...]

READ MORE
 Nascent Begins Enrollment of Final Patient Cohort to Complete Phase One Clinical Research
0
By Nascent Biotech
In Corporate News, Press Releases, Science News
Posted October 4, 2022

Nascent Begins Enrollment of Final Patient Cohort to Complete Phase One Clinical Research

VERO BEACH, FL / ACCESSWIRE / October 4, 2022 / Nascent Biotech, Inc. (OTCQB:NBIO) (“Nascent Biotech”, “Nascent”, or the “Company”), a clinical-stage [...]

READ MORE
1 2 3 4 5
page 1 of 5
© NASCENT BIOTECH, INC. ALL RIGHTS RESERVED.